Compare LND & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LND | HELP |
|---|---|---|
| Founded | 2005 | N/A |
| Country | Brazil | Canada |
| Employees | N/A | 50 |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 353.6M | 366.7M |
| IPO Year | N/A | N/A |
| Metric | LND | HELP |
|---|---|---|
| Price | $4.03 | $7.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 77.0K | ★ 579.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.65 | N/A |
| Revenue Next Year | $6.42 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.47 | $5.76 |
| 52 Week High | $4.32 | $8.23 |
| Indicator | LND | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 56.68 | 62.79 |
| Support Level | $3.56 | $7.33 |
| Resistance Level | N/A | $8.23 |
| Average True Range (ATR) | 0.11 | 0.62 |
| MACD | 0.02 | 0.17 |
| Stochastic Oscillator | 61.40 | 95.50 |
Brasilagro - Cia Bras de Prop Agricolas is a Brazil-based company, engaged in the acquisition, development, operation, and sale of rural properties suitable for agricultural activities. The business activity of the firm is operated through Real estate, Grains, Sugarcane, Cattle rising, Cotton, and Other segments. The Grains segment is involved in the production and sale of soybean and corn. The Sugarcane segment includes the sale of raw product. The Real Estate segment presents the P&L from operations carried out in the company's subsidiaries. The Cattle Raising segment consists of producing and selling beef calves after weaning, which characterizes the activity as breeding and the Other segment engages in other corporate activities. The majority of revenue is earned from Grain Segment.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.